Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (NYSE: BIO) develops, manufactures and markets instruments, systems, reagents and consumables for life science research and clinical diagnostics. Its Life Science segment serves universities, research organizations, government agencies, pharmaceutical and biotechnology companies, food… From the company’s description.
In fiscal 2025, Bio-Rad Laboratories, Inc. reported revenue of $2.58B, up 0.7% from fiscal 2024. Its operating margin was 1.8%, and operations generated $532.20M in cash. Over the twelve months to Jun 30, 2026, revenue was $2.59B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Bio-Rad Laboratories, Inc. does
In the company’s own words
Bio-Rad Laboratories, Inc. (NYSE: BIO) develops, manufactures and markets instruments, systems, reagents and consumables for life science research and clinical diagnostics. Its Life Science segment serves universities, research organizations, government agencies, pharmaceutical and biotechnology companies, food producers and testing laboratories with products used to analyze biological materials, support biopharmaceutical manufacturing and quality control, conduct food safety testing, and provide science education; this segment generated about 40% of 2025 net sales. Its Clinical Diagnostics segment supplies diagnostic test systems, informatics solutions, test kits and quality controls to hospital, reference, transfusion and physician-office laboratories, accounting for about 60% of 2025 net sales. The diagnostics portfolio supports more than 300 in vitro diagnostic tests, with instruments and consumables often combined into laboratory workflows. Bio-Rad had approximately 7,450 employees worldwide at year-end 2025 and operates directly in more than 36 countries outside the United States. It also holds a substantial investment in laboratory and process technology company Sartorius AG. Its website is www.bio-rad.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- HERCULES, CA
- Fiscal year end
- December
- CIK
- 12208
- SIC
- 3826
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Bio-Rad Laboratories, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Bio-Rad Laboratories, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
By share class
| Class | Held by funds | Funds | Shares out |
|---|---|---|---|
| BIOClass A Common Stock, Par Value $0.0001 per share | 43.9% | 350 | 21.7M |
| BIO/BClass B Common Stock, Par Value $0.0001 per share | 0.0% | 1 | 5.1M |
Bio-Rad Laboratories, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Bio-Rad Laboratories, Inc.’s debt, $162.67M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.51%, maturing 2027 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Bio-Rad Laboratories, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Bio-Rad Laboratories, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Bio-Rad Laboratories, Inc.'s last four quarterly filings that the numbers alone won't show?”